A Phase 3 interventional study of Best supportive care and Panitumumab in Colorectal Cancer and Metastases, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-07.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.
Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 10th largest by enrollment of the 88 interventional ones that give a count, is one of 4 that started in 2004, is one of 14 in phase 3, and was the 7th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
AbbVie · Sites in United States, Australia, Austria and 12 more countries
Ages 18+
R-Pharm · Sites in Russia
Ages 18+
UNICANCER · Sites in France
Ages 18+
Amgen · Sites in United States, Argentina, Australia and 32 more countries
Ages 18+
By country, each count listing its studies:
Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 68 · Phase 3 15 · Phase 4 1
First in 2000; this study’s year is marked. 4 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 463 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 70 across the 88 interventional studies. Of the 67 that completed or were terminated, 30 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 90 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
40 studies in Colorectal Neoplasms by Amgen: 2 open now, 2 under way, 1 of them phase 3. Of 38 finished, 24 (63%) have results posted.
Among the 40 studies in Colorectal Neoplasms by Amgen, this one is the 6th largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2004, is one of 10 in phase 3, and was the 6th registered.
Amgen’s Colorectal Neoplasms studies by the year they started, since 2002.
3 of the studies testing panitumumab in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03087071M.D. Anderson Cancer CenterPanitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | 2027-01-31 |
| NCT05845450Gruppo Oncologico del Nord-OvestPre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | 2027-05 |
| NCT07318389M.D. Anderson Cancer CenterASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | 2027-11-14 |
Add all 3 to your calendar (.ics) → With an account.
Among the 90 studies testing panitumumab in Colorectal Neoplasms, from their registry updates:
Among Amgen’s 40 in Colorectal Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine that panitumumab, using the proposed regimen, will safely increase progression free survival in patients with metastatic colorectal cancer who have failed available treatment options (i.e., patients who developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Panitumumab will be administered by intravenous infusion at a dose of 6 mg/kg once every 2 weeks until participants develop progressive disease or are unable to tolerate study drug. Participants will also receive best supportive care (BSC) as judged appropriate by the investigator and according to institutional guidelines.
Drug: Panitumumab
Best supportive care will be defined in this study as the best care available as judged appropriate by the investigator and according to institutional guidelines and will include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any symptomatic therapy as clinically indicated. For the purpose of this study, best supportive care will not include anti-neoplastic chemotherapy.
Other: Best supportive care
Best supportive care as site routine excluding: antineoplastic chemotherapy, investigational agents, anti-EGFr(Epidermal growth factor receptor) targeting agents other than ABX-EGF(Panitumumab), experimental or approved anti-tumor therapies (e.g. Avastin), chemotherapy, radiotherapy (with the exception of radiotherapy for pain control limited to bone metastases).
Intravenous infusion at a dose of 6 mg/kg once every 2 weeks.
Also known as: ABX-EGF
Progression-free Survival Time
Kaplan-Meier estimates of median time from randomization to either death or first observed disease progression, whichever occurred first. Participants were evaluated for tumor response according to modified Response Evaluation Criteria in Solid Tumors (RECIST) based on the response assessment from a blinded review of radiographic scans by the Independent Review Committee. Progressive disease defined as least a 20% increase in the sum of the longest diameters (SLD) of target lesions, taking as reference the nadir SLD recorded since the treatment started or the appearance of one or more new lesions, or the unequivocal progression of existing non-target lesions.
Time frame: From randomization to the data cut-off date of 30 June 2005. The median follow-up time was 20.0 weeks in the panitumumab plus BSC group and 18.2 weeks in the BSC alone group.
Overall Survival
Kaplan-Meier estimates of median time from randomization to death.
Time frame: From randomization until the data cut-off date for overall survival of 15 March 2006. The median actual follow-up time was 30 weeks for the panitumumab plus BSC group and 31 weeks for the BSC alone group.
Objective Tumor Response
Defined as the number of participants with a confirmed complete or partial tumor response, confirmed by a scan no less than 4 weeks after the criteria for response were first met. Participants were evaluated for tumor response according to modified Response Evaluation Criteria in Solid Tumors (RECIST) based on the response assessment from a blinded review of radiographic scans by the Independent Review Committee. Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions. Partial Response (PR): disappearance of all target lesions, and persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease, or, at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD, with no progressive disease of non-target lesions.
Time frame: From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.
Duration of Response
Kaplan-Meier estimate of the median time from first confirmed objective tumor response to first observed progression of disease or death due to progression of disease (whichever comes first).
Time frame: From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.
Time to Response
Time to response was defined as the time from randomization to first partial or complete response, subsequently confirmed ≥ 4 weeks after the criteria for response were first met.
Time frame: From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.
Time to Disease Progression
Kaplan-Meier estimates of median time from randomization to disease progression or death due to disease progression (whichever occurs first)
Time frame: From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.
Time to Treatment Failure
Kaplan-Meier estimate of the median time from randomization to the date the decision was made to end treatment for any reason.
Time frame: From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.
Duration of Stable Disease
Kaplan-Meier estimate of the median time from randomization to date of first observed progression of disease or death due to progression of disease (whichever comes first) for those participants with a best response of stable disease. Stable disease defined as neither sufficient shrinkage to qualify for a partial response nor sufficient increase to qualify for progressive disease taking as reference the nadir longest diameter since the treatment started, no unequivocal progression of existing non-target lesions, and no new lesions.
Time frame: From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.
Participants were enrolled from 16 January 2004 through 16 March 2005. Data are up until the data cutoff of 15 March 2007.
| Milestone | Panitumumab Plus BSC | BSC Alone |
|---|---|---|
| Started | 231 | 232 |
| Received study drug | 229 | 0 |
| Completed | 158 | 206 |
| Not completed | 73 | 26 |
| Withdrew: Adverse event | 5 | 2 |
| Withdrew: Disease progression | 28 | 14 |
| Withdrew: Lost to follow-up | 10 | 0 |
| Withdrew: Withdrawal by subject | 1 | 4 |
| Withdrew: Other | 27 | 6 |
| Withdrew: Non-compliance | 1 | 0 |
| Withdrew: Ongoing | 1 | 0 |
Kaplan-Meier estimates of median time from randomization to either death or first observed disease progression, whichever occurred first. Participants were evaluated for tumor response according to modified Response Evaluation Criteria in Solid Tumors (RECIST) based on the response assessment from a blinded review of radiographic scans by the Independent Review Committee. Progressive disease defined as least a 20% increase in the sum of the longest diameters (SLD) of target lesions, taking as reference the nadir SLD recorded since the treatment started or the appearance of one or more new lesions, or the unequivocal progression of existing non-target lesions.
| weeks | Panitumumab Plus BSC | BSC Alone |
|---|---|---|
| Progression-free Survival Time | 8.0 (7.9 to 8.4) | 7.3 (7.1 to 7.7) |
Kaplan-Meier estimates of median time from randomization to death.
| months | Panitumumab Plus BSC | BSC Alone |
|---|---|---|
| Overall Survival | 6.4 (6.1 to 7.7) | 6.3 (4.9 to 7.6) |
Defined as the number of participants with a confirmed complete or partial tumor response, confirmed by a scan no less than 4 weeks after the criteria for response were first met. Participants were evaluated for tumor response according to modified Response Evaluation Criteria in Solid Tumors (RECIST) based on the response assessment from a blinded review of radiographic scans by the Independent Review Committee. Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions. Partial Response (PR): disappearance of all target lesions, and persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease, or, at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD, with no progressive disease of non-target lesions.
| participants | Panitumumab Plus BSC | BSC Alone |
|---|---|---|
| Objective Tumor Response | 22 | 0 |
Kaplan-Meier estimate of the median time from first confirmed objective tumor response to first observed progression of disease or death due to progression of disease (whichever comes first).
| weeks | Panitumumab Plus BSC | BSC Alone |
|---|---|---|
| Duration of Response | 18.4 (16.0 to 25.3) | — |
Time to response was defined as the time from randomization to first partial or complete response, subsequently confirmed ≥ 4 weeks after the criteria for response were first met.
| weeks | Panitumumab Plus BSC | BSC Alone |
|---|---|---|
| Time to Response | 7.9 (7.3 to 10.6) | — |
Kaplan-Meier estimates of median time from randomization to disease progression or death due to disease progression (whichever occurs first)
| weeks | Panitumumab Plus BSC | BSC Alone |
|---|---|---|
| Time to Disease Progression | 8.0 (7.9 to 8.9) | 7.3 (7.1 to 7.7) |
Kaplan-Meier estimate of the median time from randomization to the date the decision was made to end treatment for any reason.
| weeks | Panitumumab Plus BSC | BSC Alone |
|---|---|---|
| Time to Treatment Failure | 9.0 (8.3 to 12.0) | 7.1 (6.4 to 7.6) |
Kaplan-Meier estimate of the median time from randomization to date of first observed progression of disease or death due to progression of disease (whichever comes first) for those participants with a best response of stable disease. Stable disease defined as neither sufficient shrinkage to qualify for a partial response nor sufficient increase to qualify for progressive disease taking as reference the nadir longest diameter since the treatment started, no unequivocal progression of existing non-target lesions, and no new lesions.
| weeks | Panitumumab Plus BSC | BSC Alone |
|---|---|---|
| Duration of Stable Disease | 24.0 (22.4 to 27.3) | 17.6 (15.4 to 25.6) |
Kaplan-Meier estimates of median time from randomization to either death or first observed disease progression among participants with wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS) status. Participants were evaluated for tumor response according to modified Response Evaluation Criteria in Solid Tumors (RECIST) based on the response assessment from a blinded review of radiographic scans by the Independent Review Committee. Progressive disease defined as least a 20% increase in the sum of the longest diameters (SLD) of target lesions, taking as reference the nadir SLD recorded since the treatment started or the appearance of one or more new lesions, or the unequivocal progression of existing non-target lesions.
| weeks | Panitumumab Plus Best Supportive Care | BSC Alone |
|---|---|---|
| Progression-free Survival Time (Wild-type KRAS) | 12.3 (8.3 to 16.1) | 7.3 (7.0 to 7.7) |
Kaplan-Meier estimates of median time from randomization to either death or first observed disease progression among participants with mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS) status. Participants were evaluated for tumor response according to modified Response Evaluation Criteria in Solid Tumors (RECIST) based on the response assessment from a blinded review of radiographic scans by the Independent Review Committee. Progressive disease defined as least a 20% increase in the sum of the longest diameters (SLD) of target lesions, taking as reference the nadir SLD recorded since the treatment started or the appearance of one or more new lesions, or the unequivocal progression of existing non-target lesions.
| weeks | Panitumumab Plus Best Supportive Care | BSC Alone |
|---|---|---|
| Progression-free Survival Time (Mutant KRAS) | 7.4 (7.3 to 7.9) | 7.3 (6.3 to 7.9) |
Collected over First dose through maximum of safety FU or 30 days after last dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panitumumab Plus BSC | — | 101/229 (44.1%) | 224/229 (97.8%) |
| BSC Alone | — | 62/234 (26.5%) | 171/234 (73.1%) |
| Event | Panitumumab Plus BSC | BSC Alone |
|---|---|---|
| COLORECTAL CANCER METASTATICNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 30/229 | 24/234 |
| COLORECTAL CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 16/229 | 9/234 |
| GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders | 14/229 | 6/234 |
| INTESTINAL OBSTRUCTIONGastrointestinal disorders | 11/229 | 4/234 |
| ABDOMINAL PAINGastrointestinal disorders | 8/229 | 8/234 |
| PYREXIAGeneral disorders | 1/229 | 8/234 |
| CONSTIPATIONGastrointestinal disorders | 7/229 | 0/234 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 6/229 | 4/234 |
| HEPATIC FAILUREHepatobiliary disorders | 5/229 | 4/234 |
| VOMITINGGastrointestinal disorders | 4/229 | 5/234 |
| Event | Panitumumab Plus BSC | BSC Alone |
|---|---|---|
| ERYTHEMASkin and subcutaneous tissue disorders | 150/229 | 2/234 |
| PRURITUSSkin and subcutaneous tissue disorders | 132/229 | 4/234 |
| DERMATITIS ACNEIFORMSkin and subcutaneous tissue disorders | 131/229 | 2/234 |
| ANOREXIAMetabolism and nutrition disorders | 63/229 | 44/234 |
| FATIGUEGeneral disorders | 59/229 | 34/234 |
| PARONYCHIAInfections and infestations | 57/229 | 0/234 |
| ABDOMINAL PAINGastrointestinal disorders | 56/229 | 36/234 |
| NAUSEAGastrointestinal disorders | 51/229 | 35/234 |
| RASHSkin and subcutaneous tissue disorders | 51/229 | 2/234 |
| DIARRHOEAGastrointestinal disorders | 48/229 | 26/234 |
| Age, Continuous(years) | Panitumumab Plus BSC | BSC Alone | Total |
|---|---|---|---|
| Mean | 61.2 ± 10.3 | 61.4 ± 10.8 | 61.3 ± 10.5 |
| Sex: Female, Male(Participants) | Panitumumab Plus BSC | BSC Alone | Total |
|---|---|---|---|
| Female | 85 | 84 | 169 |
| Male | 146 | 148 | 294 |
| Race/Ethnicity, Customized(participants) | Panitumumab Plus BSC | BSC Alone | Total |
|---|---|---|---|
| Japanese | 0 | 1 | 1 |
| Aborigine | 0 | 0 | 0 |
| Other | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White or Caucasian | 229 | 228 | 457 |
| Hispanic or Latino | 1 | 1 | 2 |
| Region of Enrollment(participants) | Panitumumab Plus BSC | BSC Alone | Total |
|---|---|---|---|
| Central and Eastern Europe | 20 | 19 | 39 |
| Western Europe | 178 | 180 | 358 |
| Rest of World | 33 | 33 | 66 |
| Eastern Cooperative Oncology Group (ECOG) performance status(participants) | Panitumumab Plus BSC | BSC Alone | Total |
|---|---|---|---|
| 0 or 1 | 200 | 202 | 402 |
| 2 | 31 | 30 | 61 |
No study locations are listed for this record.
Ran from Jan 2004 to primary completion in Oct 2008, 57 months.
Results were first posted in Jan 2014, 5 years 3 months after primary completion.
Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 57 months is above that.
Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Panitumumab